Journal
ARTHRITIS & RHEUMATOLOGY
Volume 74, Issue 1, Pages 28-32Publisher
WILEY
DOI: 10.1002/art.41924
Keywords
-
Categories
Funding
- Ben-Dov family
- National Institute of Diabetes and Digestive and Kidney Diseases, NIH [F32-DK-124941, K23-DK115908]
- National Institute of Allergy and Infectious Diseases, NIH [K24-AI-144954]
- National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH [K23-AR-073927]
Ask authors/readers for more resources
Disease flares following 2-dose SARS-CoV-2 mRNA vaccination in patients with RMDs were uncommon, with no reports of severe flares. Injection site pain and fatigue were the most frequently reported reactions. Factors such as prior SARS-CoV-2 infection, flares in the preceding 6 months, and the use of combination immunomodulatory therapy were associated with flares.
Objective To evaluate disease flare and postvaccination reactions (reactogenicity) in patients with rheumatic and musculoskeletal diseases (RMDs) following 2-dose SARS-CoV-2 messenger RNA (mRNA) vaccination. Methods RMD patients (n = 1,377) who received 2-dose SARS-CoV-2 mRNA vaccination between December 16, 2020 and April 15, 2021 completed questionnaires detailing local and systemic reactions experienced within 7 days of each vaccine dose (dose 1 and dose 2), and 1 month after dose 2, detailing any flares of RMD. Associations between demographic/clinical characteristics and flares requiring treatment were evaluated using modified Poisson regression. Results Among the patients, 11% reported flares requiring treatment; there were no reports of severe flares. Flares were associated with prior SARS-CoV-2 infection (incidence rate ratio [IRR] 2.09, P = 0.02), flares in the 6 months preceding vaccination (IRR 2.36, P < 0.001), and the use of combination immunomodulatory therapy (IRR 1.95, P < 0.001). The most frequently reported local and systemic reactions included injection site pain (87% after dose 1, 86% after dose 2) and fatigue (60% after dose 1, 80% after dose 2). Reactogenicity increased after dose 2, particularly for systemic reactions. No allergic reactions or SARS-CoV-2 diagnoses were reported. Conclusion Flares of underlying RMD following SARS-CoV-2 vaccination were uncommon. There were no reports of severe flares. Local and systemic reactions typically did not interfere with daily activity. These early safety data can help address vaccine hesitancy in RMD patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available